Compliance with results reporting at ClinicalTrials.gov

The New England Journal of Medicine
Monique L AndersonRobert M Califf

Abstract

The Food and Drug Administration Amendments Act (FDAAA) mandates timely reporting of results of applicable clinical trials to ClinicalTrials.gov. We characterized the proportion of applicable clinical trials with publicly available results and determined independent factors associated with the reporting of results. Using an algorithm based on input from the National Library of Medicine, we identified trials that were likely to be subject to FDAAA provisions (highly likely applicable clinical trials, or HLACTs) from 2008 through 2013. We determined the proportion of HLACTs that reported results within the 12-month interval mandated by the FDAAA or at any time during the 5-year study period. We used regression models to examine characteristics associated with reporting at 12 months and throughout the 5-year study period. From all the trials at ClinicalTrials.gov, we identified 13,327 HLACTs that were terminated or completed from January 1, 2008, through August 31, 2012. Of these trials, 77.4% were classified as drug trials. A total of 36.9% of the trials were phase 2 studies, and 23.4% were phase 3 studies; 65.6% were funded by industry. Only 13.4% of trials reported summary results within 12 months after trial completion, wherea...Continue Reading

References

May 20, 2000·JAMA : the Journal of the American Medical Association·E J EmanuelC Grady
Aug 11, 2005·JAMA : the Journal of the American Medical Association·David I Shalowitz, Franklin G Miller
Mar 31, 2006·The New England Journal of Medicine·Joseph Feczko
May 23, 2007·The New England Journal of Medicine·Steven E Nissen, Kathy Wolski
Jun 6, 2007·The New England Journal of Medicine·Christine LaineFreek W A Verheugt
Oct 5, 2007·The New England Journal of Medicine·Jeffrey M DrazenGregory D Curfman
Jan 18, 2008·The New England Journal of Medicine·Erick H TurnerRobert Rosenthal
Mar 4, 2011·The New England Journal of Medicine·Deborah A ZarinNicholas C Ide
Jan 5, 2012·BMJ : British Medical Journal·Andrew P PrayleAlan R Smyth
Feb 18, 2012·JAMA : the Journal of the American Medical Association·Bridget M Kuehn
May 10, 2012·JAMA : the Journal of the American Medical Association·Robert M Califf
Jul 24, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Thi-Anh-Hoa NguyenPhilippe Ravaud

❮ Previous
Next ❯

Citations

Feb 9, 2016·Drug Discovery Today·Meiping ChangWendy D Cornell
Jan 13, 2016·British Journal of Haematology·Barbara J BainRichard M Szydlo
Dec 18, 2015·Science Translational Medicine·C Michael Stein
Sep 12, 2015·Annals of the American Thoracic Society·Marcus RuoppEphraim L Tsalik
Oct 24, 2015·British Medical Bulletin·Barbara MintzesAncella Santos Quintano
Aug 2, 2015·Contemporary Clinical Trials·Charity G MooreMarie C Hogan
Mar 5, 2016·Journal of Clinical Epidemiology·John P A Ioannidis
Jul 22, 2015·Nature Reviews. Cardiology·Daniel B Kramer, Donald E Cutlip
May 21, 2015·The New England Journal of Medicine·Deborah A ZarinJoseph S Ross
Jun 20, 2015·Lancet·Françoise Baylis, Matthew Herder
Jun 11, 2015·The New England Journal of Medicine·Monique L Anderson, Eric D Peterson
May 6, 2015·Nature Reviews. Rheumatology·Fotini B Karassa, John P A Ioannidis
May 7, 2016·Journal of Clinical Pharmacology·Paul BeningerHarris Berman
Jun 5, 2016·Journal of Clinical Epidemiology·Su GolderCarmelo Sterrantino
Apr 26, 2016·Journal of Clinical Epidemiology·Bethany WithycombeDaniel M Hartung
Jul 13, 2016·Mayo Clinic Proceedings·Maria Elena FlaccoJohn P A Ioannidis
Aug 16, 2016·The New England Journal of Medicine·Elizabeth Warren
Aug 5, 2016·Nature Medicine
Aug 16, 2016·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Yu-Pei ChenJun Ma
Sep 23, 2016·Journal of Biopharmaceutical Statistics·Changyu ShenCynthia Yue
Oct 18, 2016·Journal of Comparative Effectiveness Research·Mattias NeytFrank Hulstaert
Sep 17, 2016·The New England Journal of Medicine·Deborah A ZarinSarah Carr
Aug 26, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kanwal Pratap Singh RaghavMichael J Overman
Jan 21, 2017·British Medical Bulletin·Iain Brassington
Oct 24, 2017·Research Synthesis Methods·Evan Mayo-WilsonUNKNOWN MUDS investigators
Mar 30, 2018·Personality and Social Psychology Review : an Official Journal of the Society for Personality and Social Psychology, Inc·Malte FrieseMichael Inzlicht
Nov 11, 2017·Clinical Trials : Journal of the Society for Clinical Trials·Isaretta L RileyMonique L Anderson
Mar 9, 2018·Neuro-oncology·Alyssa M VanderbeekBrian M Alexander

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.